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Chloroquine-resistant Plasmodium falciparum has 
now been reported from an increasing number of 
countries in western Africa. Recently, 2 reports 
suggested the probable emergence of chloroquine 
resistance in vivo in the Senegambian region (MENON 
et al., 1987; HELLGREN et al . ,  1987). In Senegal, 3 
isolates were found resistant in vitro in 1984/1985 
(BRANDICOURT et al . ,  1986; DRUILHE et al . ,  1986); 
however, since nearly 500 isolates studied during the 
period 1985-1988 were fully sensitive in vitro (com- 
bined unpublished data from: Brandicourt; Diouf; 
Diallo; Le Bras) and no resistant case observed in 
vivo,  Senegal was generally considered to be free from 
chloroquine resistance. 
We report here 3 cases of chloroquine resistance 
observed in October and November 1988 during a 
study conducted in Pikine, a suburb of Dakar in 
Senegal, were most children and adults are non- 
munune. 
The World Health Organization (WHO) 14-d 
extended test was successfully completed in 37 
patients aged 1-55 years with acute P .  fakiparum 
malaria. 34 (92% ) of the infections cleared after 
treatment (25 mg/kg over 3 d, tablets of Nivaquine9 
Specia) and did not recur during follow-up. 3 (8% ) of 
the infections were chloroquine-resistant (Table). 
Patient C.S. became apyretic and asymptomatic on 
day 1. Illness recurred on day 12. In vitro sensitivity 
was investigated by two methods: the standard WHO 
microtest and the 3-hypoxanthine semi-microtest. 
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Both tests indicated resistance, as schizonts matured 
in the presence of 6.4 pol/litre of chloroquine (32 
pmol per well, WHO microtest kits) and the 50% 
inhibitory concentration (IC50) was 400 nmolllitre 
(semi-microtest). Whole blood chloroquine (Cq) and 
monodesethylchloroquine (CqMI) concentrations on 
day 2 were 744 and 281 nmolllitre respectively 
(determined by high performance liquid chromo- 
tography): 
Patient B.D. became apyretic on day 1 but 
headaches were reported until day 3. Illness recurred 
on day 11. As can be seen in the Table, parasitaemia 
fluctuated markedly during follow-up, suggesting 
resistance at the RI11 level. Whole blood Cq and 
CqMl on day 2 were 966 and 140 nmoYlitre respec- 
tively. Sensitivity in vitro was not studied. 
Patient W.T. became apyretic on day 2 and 
asymptomatic (headache and weakness) on day 3. 
When the second treatment was given on day 20, 
parasite density was 29 OOO/fl and the temperature 
was 37.1"C. Careful examination and questioning 
failed to reveal any recurrence of fever or other 
symptoms. Tests in vitro indicated resistance: schi- 
zonts matured in the presence of 6.4 polllitre Cq 
(WHO microtest, day O and day 20 isolates); the ICso 
was 380 nmoYlitre (semi-microtest, day 20 isolate). 
Whole blood Cq and CqMl on day 2 were 1755 and 
545 nmoYlitre respectively (this patient had received 
20 mglkg by mistake on day 1). 
Ten years after the first report in Kenya (FOGH et 
al . ,  1979), this study demonstrates that chloroquine 
resistance in vivo has now reached the most westerly 
part of Africa. Furthermore, a high level of resistance 
was observed in 2 of the 3 first Senegalese cases, both 
of which were children who had never left the region 
of Dakar. Intensive surveys were carried out in 
Senegal during the period 1984-1988, and non- 
immune visitors to this country are numerous: it is 
interesting to note that 4 years separate the identifica- 
tion of a chloroquine-resistant strain from the emerg- 
ence of resistance in uivo. 
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